연구용

Ticagrelor P2 Receptor antagonist

제품 번호: S4079

Ticagrelor (AZD6140, AR-C 126532XX) is the first reversibly binding oral P2Y12 receptor antagonist with K_i of 2 nM.

Ticagrelor P2 Receptor antagonist Chemical Structure

화학 구조

분자량: 522.57

바로가기

품질 관리 (Quality Control)

배치: 순도: 99.88%

99.88

관련 타겟	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE)
기타 P2 Receptor 억제제	A-438079 Hydrochloride A-804598 MRS 2578 AF-353 A-740003 5-BDBD A-317491 Gefapixant Aurintricarboxylic acid Minodronic acid

세포 배양, 처리 및 작업 농도
(Cell Culture, Treatment & Working Concentration)

세포주	분석 유형	농도	배양 시간	제형	활성 설명	PMID
H9c2	Function assay	0.1, 0,3 and 1 μM	24 h		effective in reducing NCX1 reverse activity when lower concentrations
EAhy926	Apoptosis assay	40 μM and 60 μM			decrease ox-LDL-induced apoptosis, particularly at a higher concentration
AsPC-1	Function assay	10 μM	2 h		ticagrelor negated the platelet releasate effect on Akt, Erk activation and Slug upregulation
BxPC-3	Function assay	10 μM	2 h		ticagrelor negated the platelet releasate effect on Akt, Erk activation and Slug upregulation
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성 (Chemical Information, Storage & Stability)

분자량	522.57	화학식	C₂₃H₂₈F₂N₆O₄S	보관 (수령일로부터)	3년-20°C분말
CAS 번호	274693-27-5	SDF 다운로드		원액 보관	1년-80°C용매에 보관 1개월-20°C용매에 보관
동의어	AZD6140, AR-C 126532XX			Smiles	CCCSC1=NC(=C2C(=N1)N(N=N2)C3CC(C(C3O)O)OCCO)NC4CC4C5=CC(=C(C=C5)F)F

용해도 (Solubility)

In vitro
배치:

DMSO : 100 mg/mL (191.36 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 100 mg/mL (191.36 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : 100 mg/mL

Water : Insoluble

DMSO : 100 mg/mL (191.36 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : 100 mg/mL

Water : Insoluble

DMSO : 100 mg/mL (191.36 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : 100 mg/mL

Water : Insoluble

DMSO : 100 mg/mL (191.36 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : 53 mg/mL

Water : Insoluble

몰농도 계산기

질량	농도	부피	분자량
=	×	×

희석 계산기 분자량 계산기

In vivo 배치:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Selleck 연구소에서 검증되었습니다. 이 제형에 대한 조정이 필요한 경우 맞춤 테스트를 위해 당사 영업팀에 문의하십시오.	6.700mg/ml (12.82mM)	Taking the 1 mL working solution as an example, add 50 μL of 134 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

투여량: mg/kg 동물 평균 체중: g 동물당 투여량:μL 동물 수:

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH₂O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘 (Mechanism of Action)

특징	First-in-class of a new type of P2Y12 antagonist known as cyclopentyl-triazolo-pyrimidines.
Targets/IC₅₀/Ki	P2Y12 2 nM(Ki)
시험관 내(In vitro)	Ticicagrelor is an active drug which, does not require metabolic activation after intestinal absorption. It does not compete directly with ADP at the ADP binding site but occupies an adjacent binding site and acts in an allosteric way, resulting in a reversible conformational change of the receptor. This compound binds reversibly to the receptor and exhibits rapid onset and offset of effect. Binding studies in rh-P2Y12 receptor-transfected CHO-K1 cells indicate that this compound exhibits potent, rapid, and reversible binding, with a K_d of 10.5 nM, a k_on (association constant) of 0.00011/(nM•s), a k_off (dissociation constant) of 0.00087/s, and half-life values of 4 min for binding and 14 min for unbinding, indicating that the magnitude of platelet inhibition is dependent on concentrations of drug available to bind platelets. This chemical moderately inhibits CYP2C9 activity in human liver microsomes, while exhibiting little or no inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C19, CYP2D6, and CYP2E1. In human liver microsomes, it inhibits midazolam 4-hydroxylation, while activating 1_-hydroxylation of midazolam. Evaluated in fresh human hepatocytes, this compound is not an inducer of CYP1A2 or CYP3A4.
키나아제 분석	Binding assays using P2Y12-transfected CHO-K1 or humanplatelet membranes
키나아제 분석	Membranes (5 μg of protein) are added to a 96-well plate containing [¹²⁵I]AZ11931285 (125 pM), [³H]ADP (10 nM), or [³³P]2MeS-ADP (62.5 pM), the required concentration of competitor, and a sufficient volume of buffer (50 mM Tris, 5 mM MgCl₂, 50 mM NaCl, and 0.1% nucleotide-free BSA, pH 7.4) to bring the total volume in each well to 200 μL. Binding studies using platelet membranes and [³H]ADP are performed in the presence of 100 μM (final concentration) MRS2179 to prohibit binding to P2Y1. The signal-to-noise ratios for P2Y12-transfected CHO-K1 cells are approximately 14 for [³H]ADP (specific signal: 895 c.p.m.), 24 for [³³P]2MeSADP (specific signal: 3308 c.p.m.), and 24 for [¹²⁵I]AZ11931285 (specific signal: 3308 c.p.m.). For the studies using platelet membranes, the signal-to-noise ratios are approximately 2 for [³³P]2MeS-ADP and [³H]ADP and 1.5 for [¹²⁵I]AZ11931285, with a specific signal between 100 and 400 c.p.m. In this study, an incubation time of 1 h at 30 癈 is used to allow full equilibrium to be achieved. Thereafter, free radioligand is separated from bound radioligand and counted as described above.
생체 내(In vivo)	Absorption of ticagrelor is rapid with t _max of 1.3-2 h. And the C_max and area under the plasma concentration-time curve from time 0 to infinity increases in an apparently dose-proportional manner over the dose range studied, indicating linear pharmacokinetics. The mean terminal-phase half-life (t_1/2) is approximately 7-8.5 h for this compound. Inhibition of platelet aggregation (IPA) is dose related and is nearly complete at 2 h at doses of 100-400 mg. This chemical is well tolerated, with no serious or doserelated adverse events or notable changes in laboratory values observed.
참조	[1] https://pubmed.ncbi.nlm.nih.gov/19552634/ [2] https://pubmed.ncbi.nlm.nih.gov/20091161/ [3] https://pubmed.ncbi.nlm.nih.gov/21177984/ [4] https://pubmed.ncbi.nlm.nih.gov/32523112/

적용 분야 (Applications)

방법	바이오마커	이미지	PMID
Western blot	VASP-P / VASP		27694321

임상시험 정보 (Clinical Trial Information)

(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)

NCT 번호	모집	조건	스폰서/협력자	시작일	단계
NCT05774431	Recruiting	Acute Myocardial Infarction	University Hospital Heidelberg\|AstraZeneca	March 13 2023	--
NCT05283356	Recruiting	Severe Aortic Valve Stenosis\|Aortic Valve Stenosis\|Transcatheter Aortic Valve Replacement (TAVR)\|Transcatheter Aortic Valve Implantation (TAVI)	Fundacin Biomedica Galicia Sur	January 21 2022	Phase 4

product.CellLines}	product.AssayType}	product.Concentration}	product.IncubationTime}	product.Formulation}	product.ActivityDescription}	PMID

희석 계산기

스톡 솔루션 준비에 필요한 희석을 계산하십시오. Selleck 희석 계산기는 다음 방정식을 기반으로 합니다.

농도 _(시작) x 볼륨 _(시작) = 농도 _(최종) x 볼륨 _(최종)

이 방정식은 일반적으로 다음과 같이 약칭됩니다. C1V1 = C2V2 ( 입력 출력 )

*스톡 용액을 준비할 때는 항상 바이알 라벨 및 MSDS / COA (온라인에서 사용 가능)에 있는 제품의 배치별 분자량을 사용하십시오.

연속 희석 계산기 방정식

연속 희석

농도 (시작):

희석 배율:

계산된 결과

C1=C0/X	C1:		LOG(C1):
C2=C1/X	C2:		LOG(C2):
C3=C2/X	C3:		LOG(C3):
C4=C3/X	C4:		LOG(C4):
C5=C4/X	C5:		LOG(C5):
C6=C5/X	C6:		LOG(C6):
C7=C6/X	C7:		LOG(C7):
C8=C7/X	C8:		LOG(C8):